idose tr (Glaukos Corporation)

iDose TR is a **biocompatible, intracameral drug delivery implant** containing 75 mcg of travoprost, a prostaglandin analog, designed for the **long-term reduction of intraocular pressure (IOP)** in patients with open-angle glaucoma or ocular hypertension[1][2][3][13][14]. The implant uses a proprietary membrane to deliver continuous, controlled amounts of travoprost directly to the anterior chamber, improving patient adherence and minimizing the need for daily eye drops[2][3][8][9]. Travoprost is a selective FP prostanoid receptor agonist that increases uveoscleral outflow, thereby lowering IOP; the exact detailed molecular mechanism is not fully established[1][3][4][14]. The device is anchored within the sclera at the iridocorneal angle and typically remains effective for at least 12 months, often longer[2][9]. Developed and marketed by Glaukos, iDose TR received FDA approval for its primary indication based on robust pivotal trials demonstrating safety and efficacy in long-term IOP control[1][13][14].

Brand names

iDose TR

Other names

travoprost intracameral implant